Recruiting

Observational Study

Sponsor:

The POLG Foundation

Code:

NCT07775872

Conditions

PolG, Primary Mitochondrial Myopathy

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The PIONEER study is a prospective, natural history study dedicated to characterizing the clinical progression of POLG-related disorders. The research aims to bridge the gap between genetic diagnosis and drug development by mapping how these rare mitochondrial conditions evolve over time. By observing the disease's natural trajectory through a multi-center approach, The study identifies critical clinical milestones that serve as a foundation for evaluating therapeutic efficacy and future therapeutic interventions

Conditions

PolG, Primary Mitochondrial Myopathy

Study ID

NCT07775872

Start date

Jun 17, 2026

Status verified date

Nov, 2026

Completion date

Jun 17, 2031

Anticipated

Primary completion date

Jun 17, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • male \& female from age 0 to 75.
  • A genetically confirmed POLG -associated disorder based on both phenotype and genotype is required.
  • Parental/guardian permission (informed consent) and if appropriate with child assent.

Exclusion Criteria:

  • Diagnosis of mitochondrial disorder other than POLG
  • Subject with POLG Variant of unknown significance or benign variant.
  • Parents/guardians or subjects who, in the opinion of the investigator, may be non-compliant with the study schedules or procedures.
  • Subjects unable or unwilling to provide informed consent.
  • History of or current clinically important condition other than what is related to the PMD which, in the opinion of the Investigator will confound the results of the NHS.

Study Design

Enrollment

200 participants

Anticipated

Interventions and Outcome Measures

Arms

Single Observational Cohort

Single Observational Cohort: Individuals (Pediatric and Adults) with genetically confirmed POLG-related disorders. No intervention is administered. Participants undergo longitudinal clinical assessments, patient-reported outcomes, biomarker collection, and review of routine clinical data.

Primary outcome measure

  • Scale for the Assessment and Rating of Ataxia (SARA) [ Time Frame: Baseline through 36 months (every 12 months) ]

Central Contacts and Locations

Locations

Akron Children's Hospital

Recruiting

Akron, Ohio, United States, 44308

Contacts

Principal Investigator:

Bruce Cohen

Children's Hospital of Philadelphia-Philadelphia

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

UTHealth Houston

Recruiting

Houston, Texas, United States, 77030

Contacts

Principal Investigator:

Mary Kay Koeing

More Information

Sponsor

The POLG Foundation

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Keywords

  • POLG
  • POLG disease
  • Primary Mitochondrial Disease
  • Mitochondrial DNA Depletion Syndrome
  • Fibroblast Growth Factor 21 (FGF21)
  • Growth Differentiation Factor 15 (GDF15)
  • Epilepsy
  • Seizures
  • Ataxia
  • Progressive External Ophthalmoplegia
  • Neuropathy
  • Mitochondrial Myopathy
  • Natural History Study

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by The POLG Foundation on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.